--- title: "Lifeward Delays Quarterly Report Amid Deal Accounting" type: "News" locale: "en" url: "https://longbridge.com/en/news/286586728.md" description: "Lifeward (LFWD) has announced a delay in filing its Form 10-Q for the quarter ended March 31, 2026, due to complex accounting related to a recent strategic transaction. The company expects a 22% revenue decline and a projected net loss increase of 123%. Lifeward aims to file the report within five days of the original due date. The latest analyst rating for LFWD is a Buy with a $10.00 price target, though Spark's AI Analyst rates it as Neutral due to ongoing financial challenges." datetime: "2026-05-15T14:17:56.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286586728.md) - [en](https://longbridge.com/en/news/286586728.md) - [zh-HK](https://longbridge.com/zh-HK/news/286586728.md) --- # Lifeward Delays Quarterly Report Amid Deal Accounting Lifeward ( (LFWD) ) has released a notification of late filing. ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Lifeward Ltd. has filed a Form 12b-25 to notify investors that it will be late in filing its Form 10-Q (Quarter Report) for the quarter ended March 31, 2026. The delay relates specifically to this Form 10-Q (Quarter Report), which covers the company’s most recent three-month financial period. The company cites a recently completed strategic transaction on March 25, 2026 as the main reason for the late filing. Management says the transaction involves complex valuation and accounting treatment, requiring extra time to complete the associated analyses and ensure the financial statements comply with applicable accounting standards. Lifeward states it expects to file the delayed Form 10-Q (Quarter Report) within five calendar days of the original due date. The company also confirms that all other required periodic reports over the past 12 months have been filed on time. The upcoming Form 10-Q (Quarter Report) is expected to show a roughly 22% revenue decline, or about $1.1 million, compared with the same quarter in 2025. Net loss is projected to increase by about $6.0 million, or 123%, largely due to a one-time $4.9 million research and development charge tied to acquired in-process R&D from the strategic transaction, plus about $0.6 million of financing expenses related to an Oramed loan and derivative remeasurement. Revenue weakness mainly stems from lower AlterG unit shipments in the U.S. and internationally, which management links to working capital constraints affecting sourcing and supply chain timing, partially offset by higher ReWalk revenue. The company stresses that these figures are preliminary, forward-looking in nature, and may change as the reporting process and final Form 10-Q (Quarter Report) are completed. Lifeward indicates it is focusing on finalizing its accounting review and maintaining reporting compliance as it completes the quarter’s financials. The notification is signed on behalf of the company by President and Chief Executive Officer William Mark Grant, dated May 15, 2026, underscoring executive responsibility for the filing and ongoing disclosure obligations. The most recent analyst rating on (LFWD) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Lifeward stock, see the LFWD Stock Forecast page. **Spark’s Take on LFWD Stock** According to Spark, TipRanks’ AI Analyst, LFWD is a Neutral. LFWD scores low primarily due to persistently weak financial performance (continued losses, significant cash burn, and a weakened equity position) and soft technical momentum (below major moving averages with negative MACD). Corporate events reduce some near-term listing overhang and add financing/strategy progress, but funding terms and ongoing execution/liquidity risk keep the overall score subdued. To see Spark’s full report on LFWD stock, click here. **More about Lifeward** **Average Trading Volume:** 15,632 **Technical Sentiment Signal:** Sell **Current Market Cap:** $10.08M For a thorough assessment of LFWD stock, go to TipRanks’ Stock Analysis page. ### Related Stocks - [LFWD.US](https://longbridge.com/en/quote/LFWD.US.md) - [XHE.US](https://longbridge.com/en/quote/XHE.US.md) - [IHI.US](https://longbridge.com/en/quote/IHI.US.md) - [ORMP.US](https://longbridge.com/en/quote/ORMP.US.md) ## Related News & Research - [Picard Medical / SynCardia Reports First Quarter 2026 Financial Results](https://longbridge.com/en/news/287208915.md) - [Edwards Lifesciences CVP, Strategy/Corp Development Sold Shares Worth Over $1.4M](https://longbridge.com/en/news/286822028.md) - [Orthofix Medical updates 2026 outlook after CMS Medicare cuts for bone growth stimulators](https://longbridge.com/en/news/287216169.md) - [Jenscare’s LuX-Valve Plus Shows Strong One-Year Results in Large Annulus Tricuspid Patients](https://longbridge.com/en/news/287144318.md) - [Forward Industries Q2 revenue rises over 4x, posts $283 mln net loss](https://longbridge.com/en/news/286466469.md)